Trials / Terminated
TerminatedNCT00821717
EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure
A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferinject ® (Ferric carboxymaltose) | Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit. After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase). |
| DRUG | Normal saline (0.9%) | During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-10-01
- Completion
- 2011-01-01
- First posted
- 2009-01-13
- Last updated
- 2015-06-03
Locations
41 sites across 5 countries: Denmark, France, Germany, Israel, Netherlands
Source: ClinicalTrials.gov record NCT00821717. Inclusion in this directory is not an endorsement.